We believe linvoseltamab has the potential to be the ... being a better way of administering the product than out of a vial for patients getting intravitreal injections. So, boil all that down ...

Regeneron’s bispecific antibody linvoseltamab has received conditional approval from the European Commission (EC) for use in relapsed or refractory multiple myeloma. The decision comes just eight ...

“In a clinical trial, linvoseltamab demonstrated compelling and impressive efficacy with the potential for complete remission in this patient population, including those with high disease burde ...

For those who develop relapsed and refractory disease after having been exposed to the three major drug classes, it's important to have new therapies with different mechanisms of action like ...

"In a clinical trial, linvoseltamab demonstrated compelling and impressive efficacy with the potential for complete remission in this patient population, including those with high disease burden.

“Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma, and in clinical trials, our investigational BCMAxCD3 bispecific antibody linvoseltamab has ...